Abstract
Purpose: :
To assess the safety and effectiveness of the AcrySof phakic angle-supported intraocular lens (Cachet pIOL, Alcon Laboratories, Inc., Fort Worth, TX) for correction of moderate to high myopia in adults.
Methods: :
19 eyes of 10 patients with moderate to high myopia were implanted with an AcrySof Cachet pIOL. Manifest refraction spherical equivalent (MRSE), uncorrected distance visual acuity (UCVA) and best spectacle-corrected visual acuity (BSCVA) and endothelial cell density (ECD) were evaluated both preoperatively and 6-months postoperatively.
Results: :
Mean (±SD) age of the population study was 38.26 (±8.98) years old. The mean preoperative MRSE was -9.49 ± 3.08 diopters (D; range -6.00 to -16.75 D). The 6-months postoperative mean MRSE was -0.29 D (± 0.41; P<0.001). The mean (±SD) preoperative and 6-months postoperative ECD were 2829 ± 301 cell/mm2 and 2902 ± 334 cell/mm2 respectively (P=0.67). No iridotomy was performed preoperatively. No pupil ovalization or pupillary block were observed postoperatively.
Conclusions: :
The AcrySof phakic angle-supported IOL yielded excellent refractive correction and predictability for the correction of moderate and high myopia, with no change in ECD count during a 6-months follow-up.
Keywords: intraocular lens • refractive surgery: phakic IOL